MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

So, you like games? Vulture’s Movies Fantasy League just kicked off its new season. It’s fun, it’s free, and there are some killer prizes on the line. Sign up to play here, or learn more at the MFL ...

I've been testing PC and mobile software for more than 20 years, focusing on photo and video editing, operating systems, and web browsers. Prior to my current role, I covered software and apps for ...

Independent news. Trusted by Texans. About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics | Republish Our Work | Jobs | Awards | Corrections | Strategic Plan | Downloads | ...